According to our data, we could not detect a significant effect of neoadjuvant treatment on FGFR2-amplified tumor clones, as we found no significant differences in the distribution of FGFR2-amplified tumors in naïve or pretreated adenocarcinomas of the upper GIT. This evidence concerns the gene FGFR2 and adenocarcinoma.